// App-Quantinova.ai

e21073 : Imatinib versus interferon as adjuvant therapy in a phase II study in patients with highrisk C-Kit mutated melanoma.

Researchers

Presenter

  • Li Li Mao

Principal Investigators

  • Lu Si

  • Yan Kong

  • Xuan Wang

  • BIN LIAN

  • Zhihong Chi

  • Chuanliang Cui

  • Xinan Sheng

  • Jun Guo

Medical Centers

  • Peking University Cancer Hospital & Institute, Beijing, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Melanoma

Biomarkers

  • KIT Proto-Oncogene, Receptor Tyrosine Kinase

Drug/Treatment

  • Interferon

  • Imatinib

  • IkT001

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • II

Study Id's

  • NCT01782508

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved